MedTrace Logo

Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma

NCT00284271 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2011-07-29

No results posted yet for this study

Summary

This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.

Conditions

  • Hodgkin´s Lymphoma

Interventions

DRUG

Cyclophosphamide

DRUG

Adramycin

DRUG

Procarbacine

DRUG

Prednisone

DRUG

Vincristine

DRUG

Bleomycin

DRUG

Erythropoietin beta

Sponsors & Collaborators

  • University of Cologne

    lead OTHER

Principal Investigators

  • Andreas Josting, Dr. · University of Cologne

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
61 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2005-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00284271 on ClinicalTrials.gov